PL3453387T3 - Schemat dawkowania dla agonisty receptora s1p - Google Patents

Schemat dawkowania dla agonisty receptora s1p

Info

Publication number
PL3453387T3
PL3453387T3 PL18201062T PL18201062T PL3453387T3 PL 3453387 T3 PL3453387 T3 PL 3453387T3 PL 18201062 T PL18201062 T PL 18201062T PL 18201062 T PL18201062 T PL 18201062T PL 3453387 T3 PL3453387 T3 PL 3453387T3
Authority
PL
Poland
Prior art keywords
receptor agonist
dosing chart
dosing
chart
agonist
Prior art date
Application number
PL18201062T
Other languages
English (en)
Inventor
Robert Schmouder
Thomas Dumortier
Olivier David
Michael Looby
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41667217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3453387(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3453387T3 publication Critical patent/PL3453387T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL18201062T 2008-12-22 2009-12-21 Schemat dawkowania dla agonisty receptora s1p PL3453387T3 (pl)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US13967208P 2008-12-22 2008-12-22
US21853009P 2009-06-19 2009-06-19
US24671509P 2009-09-29 2009-09-29
EP09797234.3A EP2379067B1 (en) 2008-12-22 2009-12-21 Dosage regimen for fingolimod for the treatment of multiple sclerosis
EP16182876.9A EP3120844A1 (en) 2008-12-22 2009-12-21 Dosage regimen for a s1p receptor agonist
EP18201062.9A EP3453387B1 (en) 2008-12-22 2009-12-21 Dosage regimen for a s1p receptor agonist
PCT/US2009/068888 WO2010075239A1 (en) 2008-12-22 2009-12-21 Dosage regimen for a s1p receptor agonist
EP15158251.7A EP2907511A1 (en) 2008-12-22 2009-12-21 Dosage regimen for a s1p receptor agonist

Publications (1)

Publication Number Publication Date
PL3453387T3 true PL3453387T3 (pl) 2020-11-02

Family

ID=41667217

Family Applications (4)

Application Number Title Priority Date Filing Date
PL22187007.4T PL4098256T3 (pl) 2008-12-22 2009-12-21 Schemat dawkowania dla agonisty receptora s1p
PL09797234T PL2379067T3 (pl) 2008-12-22 2009-12-21 Schemat dawkowania fingolimodu w leczeniu stwardnienia rozsianego
PL18201062T PL3453387T3 (pl) 2008-12-22 2009-12-21 Schemat dawkowania dla agonisty receptora s1p
PL18179301T PL3409274T3 (pl) 2008-12-22 2009-12-21 Schemat dawkowania dla agonisty receptora s1p

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL22187007.4T PL4098256T3 (pl) 2008-12-22 2009-12-21 Schemat dawkowania dla agonisty receptora s1p
PL09797234T PL2379067T3 (pl) 2008-12-22 2009-12-21 Schemat dawkowania fingolimodu w leczeniu stwardnienia rozsianego

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18179301T PL3409274T3 (pl) 2008-12-22 2009-12-21 Schemat dawkowania dla agonisty receptora s1p

Country Status (43)

Country Link
US (12) US20100160259A1 (pl)
EP (7) EP4098256B9 (pl)
JP (7) JP2012513401A (pl)
KR (1) KR101347919B1 (pl)
CN (1) CN102264359A (pl)
AR (1) AR074826A1 (pl)
AU (1) AU2009330176C9 (pl)
BR (1) BRPI0923500A2 (pl)
CA (1) CA2747802C (pl)
CL (2) CL2011001529A1 (pl)
CO (1) CO6390117A2 (pl)
CR (1) CR20110274A (pl)
CU (1) CU20110136A7 (pl)
CY (5) CY1116990T1 (pl)
DK (4) DK3409274T3 (pl)
EA (1) EA201100978A1 (pl)
EC (1) ECSP11011222A (pl)
ES (4) ES2760607T3 (pl)
FI (2) FI4098256T3 (pl)
FR (2) FR20C1060I1 (pl)
HN (1) HN2011001759A (pl)
HR (4) HRP20250568T1 (pl)
HU (6) HUE026869T2 (pl)
IL (3) IL213170A0 (pl)
LT (5) LT3453387T (pl)
LU (1) LUC00183I2 (pl)
MA (1) MA32981B1 (pl)
ME (2) ME03802B (pl)
MX (3) MX2011006623A (pl)
NO (1) NO2020038I1 (pl)
NZ (1) NZ593065A (pl)
PE (1) PE20120337A1 (pl)
PL (4) PL4098256T3 (pl)
PT (4) PT3409274T (pl)
RS (3) RS66784B9 (pl)
SG (1) SG171404A1 (pl)
SI (4) SI2379067T1 (pl)
SM (2) SMT202000441T1 (pl)
TN (1) TN2011000272A1 (pl)
TW (1) TW201028143A (pl)
UY (1) UY32352A (pl)
WO (1) WO2010075239A1 (pl)
ZA (2) ZA201103863B (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2716448A1 (en) 2008-03-17 2009-09-24 Patrick Brossard Dosing regimen for a selective s1p1 receptor agonist
US20100160259A1 (en) 2008-12-22 2010-06-24 Robert Schmouder Dosage regimen for a s1p receptor agonist
EP3831371A1 (en) 2009-09-29 2021-06-09 Novartis AG Dosage regimen of an s1p receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2011138398A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Dosage regimen of diaryl sulfide derivatives
EP2455080A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
SG191286A1 (en) 2011-01-07 2013-07-31 Novartis Ag Immunosuppressant formulations
ES2716865T3 (es) 2011-02-18 2019-06-17 Scripps Research Inst Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
US9592268B2 (en) 2011-05-23 2017-03-14 Cornell University Endothelium protective materials and methods of use
TW201320994A (zh) 2011-10-11 2013-06-01 Novartis Ag 投藥療程
HUE050733T2 (hu) 2012-08-17 2021-01-28 Actelion Pharmaceuticals Ltd Eljárás (2Z,5Z)-5-(3-klór-4-((R)-2,3-dihidroxipropoxi)benzilidén)-2-(pro-pilimino)-3-(O-tolil)tiazolidin-4-on elõállítására és ezen eljárásban alkalmazott köztitermék
US20160129084A1 (en) * 2013-03-06 2016-05-12 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure
EP3054933A4 (en) 2013-10-11 2017-03-15 Teikoku Pharma USA, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
WO2015053879A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
CN106456552A (zh) * 2014-04-10 2017-02-22 诺华股份有限公司 S1p调节剂的立即释放剂量方案
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
HUE057865T2 (hu) 2014-12-11 2022-06-28 Actelion Pharmaceuticals Ltd A poneszimodra, egy szelektív S1P1 receptor agonistára vonatkozó adagolási rend
CA3002540C (en) * 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
KR20190113955A (ko) 2017-02-16 2019-10-08 아레나 파마슈티칼스, 인크. 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態を治療する方法
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
AU2021228371A1 (en) * 2020-02-28 2022-10-13 Akaal Pharma Pty Ltd S1P receptor modulators
CN113332435B (zh) * 2021-06-18 2022-10-18 广州中医药大学(广州中医药研究院) 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0155015B1 (ko) 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
JP5227492B2 (ja) 2002-05-16 2013-07-03 ノバルティス アーゲー 癌におけるｅｄｇレセプター結合剤の使用
WO2005025553A2 (en) * 2003-09-12 2005-03-24 Neuronova Ab Treatment of disorders of nervous systemsystem with fty720
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
EP2384749A1 (en) * 2004-11-29 2011-11-09 Novartis AG Dosage regimen of an S1P receptor agonist
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
CN101541227B (zh) * 2005-02-10 2013-06-05 G.I.视频有限公司 用于带导向元件的胃肠工具的前进技术
WO2009048993A2 (en) * 2007-10-12 2009-04-16 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
CA2716448A1 (en) * 2008-03-17 2009-09-24 Patrick Brossard Dosing regimen for a selective s1p1 receptor agonist
WO2009155475A1 (en) * 2008-06-20 2009-12-23 Novartis Ag Paediatric compositions for treating1 multiple sclerosis
US20100160259A1 (en) 2008-12-22 2010-06-24 Robert Schmouder Dosage regimen for a s1p receptor agonist
MX367667B (es) * 2008-12-22 2019-08-30 Novartis Ag Régimen de dosificación de un agonista de los receptores de s1p.

Also Published As

Publication number Publication date
PL2379067T3 (pl) 2016-02-29
AU2009330176C9 (en) 2017-01-05
CY2020036I2 (el) 2021-06-25
US20180289638A1 (en) 2018-10-11
LTPA2025520I1 (pl) 2025-06-25
ME03802B (me) 2021-04-20
RS60666B1 (sr) 2020-09-30
DK4098256T5 (da) 2025-07-21
JP2024129030A (ja) 2024-09-26
HUE048717T4 (hu) 2022-02-28
FI4098256T3 (fi) 2025-03-31
PT4098256T (pt) 2025-04-10
US20170189353A1 (en) 2017-07-06
JP2022103194A (ja) 2022-07-07
SMT202000054T1 (it) 2020-03-13
MX385959B (es) 2025-03-18
CY2025012I1 (el) 2026-02-25
EP3120844A1 (en) 2017-01-25
SG171404A1 (en) 2011-07-28
CY1122812T1 (el) 2021-05-05
CO6390117A2 (es) 2012-02-29
AU2009330176B2 (en) 2014-03-06
PE20120337A1 (es) 2012-04-24
MX2011006623A (es) 2011-07-12
RS66784B9 (sr) 2025-08-29
HUS2500026I1 (hu) 2025-07-28
ZA201103863B (en) 2012-10-31
BRPI0923500A2 (pt) 2018-05-29
IL278914A (en) 2021-01-31
US20140148415A1 (en) 2014-05-29
JP7329965B2 (ja) 2023-08-21
HRP20192175T1 (hr) 2020-03-20
LT3453387T (lt) 2020-08-25
DK3453387T3 (da) 2020-08-10
DK4098256T3 (da) 2025-04-22
NZ593065A (en) 2012-11-30
HUE026869T2 (en) 2016-08-29
AU2009330176A1 (en) 2011-07-07
JP2014144970A (ja) 2014-08-14
ES2760607T3 (es) 2020-05-14
EP3409274B1 (en) 2019-11-20
RS59857B1 (sr) 2020-02-28
PT2379067E (pt) 2015-12-23
EP2379067B1 (en) 2015-09-02
LT3409274T (lt) 2020-02-10
US20220142949A1 (en) 2022-05-12
AR074826A1 (es) 2011-02-16
MX2021010759A (es) 2022-07-19
SI2379067T1 (sl) 2016-01-29
CL2011001529A1 (es) 2012-02-24
KR20110096175A (ko) 2011-08-29
RS66784B1 (sr) 2025-06-30
HRP20201167T1 (hr) 2020-12-11
SMT202000441T1 (it) 2020-09-10
LUC00183I2 (pl) 2024-07-01
HRP20151190T1 (hr) 2016-01-01
US20110257133A1 (en) 2011-10-20
EP3453387A1 (en) 2019-03-13
ES2552823T3 (es) 2015-12-02
HRP20250568T1 (hr) 2025-07-04
HUE052048T2 (hu) 2021-04-28
CL2013001558A1 (es) 2013-10-25
CY1123255T1 (el) 2021-10-29
FIC20253002I1 (fi) 2025-05-23
FR25C1012I1 (fr) 2025-06-13
CY2025012I2 (el) 2026-02-25
HUE048717T2 (hu) 2020-08-28
UY32352A (es) 2010-07-30
EP3453387B1 (en) 2020-06-03
US20250262171A1 (en) 2025-08-21
NO2020038I1 (no) 2020-11-18
LTPA2020005I1 (lt) 2020-12-10
TN2011000272A1 (en) 2012-12-17
CY2020036I1 (el) 2021-03-12
CN102264359A (zh) 2011-11-30
SI3409274T1 (sl) 2020-03-31
EP4098256A1 (en) 2022-12-07
SI4098256T1 (sl) 2025-06-30
US20160081949A1 (en) 2016-03-24
EP4098256B9 (en) 2025-06-18
US20140066657A1 (en) 2014-03-06
EP2379067A1 (en) 2011-10-26
WO2010075239A1 (en) 2010-07-01
JP2012513401A (ja) 2012-06-14
ES2810823T3 (es) 2021-03-09
EA201100978A1 (ru) 2012-01-30
EP4098256B1 (en) 2025-02-26
EP3677260A1 (en) 2020-07-08
EP2907511A1 (en) 2015-08-19
IL274756A (en) 2020-07-30
LT4098256T (lt) 2025-06-10
HUS2000046I1 (hu) 2020-12-28
IL213170A0 (en) 2011-07-31
PL3409274T3 (pl) 2020-06-01
FR20C1060I1 (fr) 2020-12-25
US20190091180A1 (en) 2019-03-28
MA32981B1 (fr) 2012-01-02
JP2019167360A (ja) 2019-10-03
US20100160259A1 (en) 2010-06-24
KR101347919B1 (ko) 2014-01-07
EP3409274A1 (en) 2018-12-05
HUE071189T2 (hu) 2025-08-28
JP2016135752A (ja) 2016-07-28
SI3453387T1 (sl) 2020-10-30
JP2017141238A (ja) 2017-08-17
ZA201205942B (en) 2013-03-27
DK2379067T3 (en) 2015-12-07
ECSP11011222A (es) 2011-08-31
CR20110274A (es) 2011-07-19
TW201028143A (en) 2010-08-01
AU2009330176C1 (en) 2016-12-08
ES3017254T3 (en) 2025-05-12
PT3453387T (pt) 2020-08-11
CA2747802C (en) 2021-02-09
DK3409274T3 (da) 2019-12-16
US20200330407A1 (en) 2020-10-22
PL4098256T3 (pl) 2025-06-09
ME03594B (me) 2020-07-20
HN2011001759A (es) 2013-11-26
CA2747802A1 (en) 2010-07-01
CU20110136A7 (es) 2012-01-31
US20160263061A1 (en) 2016-09-15
PT3409274T (pt) 2019-12-17
CY1116990T1 (el) 2017-04-05

Similar Documents

Publication Publication Date Title
LTPA2020513I1 (lt) S1P receptoriaus agonisto dozavimas
CY2025012I2 (el) Δοσολογικο σχημα για εναν αγωνιστη των υποδοχεων s1p
HRP20170246T1 (hr) Režim doziranja za selektivni agonist s1p1-receptora
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
BRPI0923512A2 (pt) antagonistas de receptores de ácido lisofosfatídico
DK2252581T3 (da) Kappa-selektiv opioidreceptorantagonist
DK2358686T3 (da) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
DK2381986T3 (da) Lægemiddeladministrationsanordning
LT2593452T (lt) Heterocikliniai junginiai, kaip ip receptoriaus agonistai
BRPI0918064A2 (pt) distribuidor de substância
DK2200752T3 (da) Doseringsindretning
PT2317852E (pt) Formulações farmacêuticas contendo ligandos de recetor de dopamina
BRPI0914942A2 (pt) Compostos de oxindol
BRPI0906705A2 (pt) Composto heterocíclicos
BRPI0915781A2 (pt) oxazolopiridimas como agonista do receptor edg-1
BR112013002096A2 (pt) compostos de agonistas de receptor glp-1 possuindo regiões estabilizadas
DK2334897T3 (da) Forbedret styringssystem
HRP20150932T1 (xx) Heterocikliäśki spojevi
BR112012002824A2 (pt) agonistas de receptor de esfingosina-1-fosfato
DK2342060T3 (da) Doseringsindretning
DK2323933T3 (da) Stableenhed
BRPI0923891A2 (pt) dispositivo de dosagem
DK2319515T3 (da) Coccidicid kombination til veterinær anvendelse
NO20083270L (no) Indolforbindelser
FI20080235A0 (fi) Sovitinkomponentti mittausjärjestelmään